Chenmu Du
YOU?
Author Swipe
View article: Figure S2 from A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia
Figure S2 from A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia Open
Major response rate by subgroup in Chinese patients with R/R WM, as assessed by the investigator.
View article: Supplementary Data from A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia
Supplementary Data from A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia Open
Cover page
View article: Table S3 from A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia
Table S3 from A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia Open
Time to disease response in Chinese patients with R/R WM receiving zanubrutinib, as assessed by the investigator.
View article: Figure S3 from A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia
Figure S3 from A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia Open
Median immunoglobulin M and hemoglobin over time in Chinese patients with R/R WM receiving zanubrutinib.
View article: Data from A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia
Data from A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia Open
Purpose:Although Bruton tyrosine kinase (BTK) inhibitors have demonstrated promising efficacy in patients with Waldenström macroglobulinemia (WM), data in Asian populations are scarce. This trial is the first to investigate the effect of a…
View article: Table S2 from A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia
Table S2 from A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia Open
Prior systemic therapies and best response to last systemic regimen in Chinese patients with R/R WM.
View article: Figure S1 from A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia
Figure S1 from A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia Open
Study design.
View article: Table S1 from A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia
Table S1 from A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia Open
Mutation status and bone marrow involvement by biopsy at baseline in Chinese patients with R/R WM.
View article: A two‐part, single‐arm, multicentre, phase I study of zanubrutinib, a selective <scp>Bruton tyrosine kinase</scp> inhibitor, in Chinese patients with relapsed/refractory B‐cell malignancies
A two‐part, single‐arm, multicentre, phase I study of zanubrutinib, a selective <span>Bruton tyrosine kinase</span> inhibitor, in Chinese patients with relapsed/refractory B‐cell malignancies Open
Summary This single‐arm, multicentre, phase I study is the first study of zanubrutinib, a potent, specific, irreversible Bruton tyrosine kinase (BTK) inhibitor, in Chinese patients with relapsed/refractory B‐cell malignancies. The objectiv…
View article: Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies
Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies Open
Zanubrutinib is a selective Bruton tyrosine kinase (BTK) inhibitor evaluated in multiple B-cell malignancy studies. We constructed a pooled safety analysis to better understand zanubrutinib-associated treatment-emergent adverse events (TEA…
View article: A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia
A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia Open
Purpose: Although Bruton tyrosine kinase (BTK) inhibitors have demonstrated promising efficacy in patients with Waldenström macroglobulinemia (WM), data in Asian populations are scarce. This trial is the first to investigate the effect of …
View article: PS1159 POOLED ANALYSIS OF SAFETY DATA FROM MONOTHERAPY STUDIES OF THE BRUTON TYROSINE KINASE (BTK) INHIBITOR, ZANUBRUTINIB (BGB‐3111), IN B‐CELL MALIGNANCIES
PS1159 POOLED ANALYSIS OF SAFETY DATA FROM MONOTHERAPY STUDIES OF THE BRUTON TYROSINE KINASE (BTK) INHIBITOR, ZANUBRUTINIB (BGB‐3111), IN B‐CELL MALIGNANCIES Open
Background: Zanubrutinib, a next generation BTK inhibitor, achieves high plasma concentrations and sustained complete BTK occupancy in blood and lymph nodes, with greater selectivity for BTK vs other TEC and EGFR family kinases in biochemi…